影响维吾尔族非小细胞肺癌预后的因素分析
摘要
目的分析影响维吾尔族非小细胞肺癌(NSCLC)患者预后因素。方法选取2005-2014年在该院就诊的453例维吾尔族NSCLC患者为研究对象,对患者的临床分期、病理类型、驱动基因等临床资料进行对比分析及随访。结果随访时间截止2017年12月31日,明确死亡患者369例,其中死于肺癌的患者343例,26例患者死于包括心脑血管疾病在内的其他疾病。单因素分析显示:女性(P=0.010),TNM分期(P=0.000),有EGFR突变(P=0.000),有吸烟史(P=0.014),与维吾尔族NSCLC患者的预后相关;多因素分析中仅提示TNM分期(P=0.000)与预后相关。结论维吾尔族NSCLC患者有其民族的特点,TNM分期是影响维吾尔族NSCLC患者预后的独立因素。
引文
[1]马晓梅,姬文莉,王翠翠,等.新疆维吾尔族及汉族原发性肺癌临床病理特征分析[J].新疆医科大学学报,2014,37(3):325-327,331.
[2]RAMALINGAM S S,OWONIKOKO T K,KHURI F R.Lung cancer:new biological insights and recent therapeutic advances[J].CA Cancer J Clin,2011,61(2):91-112.
[3]彭红,韩宝惠,李小青,等.1 279例肺癌患者临床特征及生存率分析[J].中国癌症杂志,2011,21(5):354-358.
[4]SACHER A G,DAHLBERG S E,HENG J,et al.Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer[J].JAMA Oncol,2016,2(3):313-320.
[5]WANG Y,CHEN J,DING W,et al.Clinical features and gene mutations of lung cancer patients 30years of age or younger[J].PLoS One,2015,10(9):e0136659.
[6]张仁锋,张岩,温丰标,等.6 058例肺癌患者病理类型和临床流行病学特征的分析[J].中国肺癌杂志,2016,19(3):129-135.
[7]AYYOUB M,MEMEO L,ALVAREZ-FERNNDEZ E,et al.Assessment of MAGE-A expression in resected nonsmall cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS[J].Cancer Immunol Res,2014,2(10):943-948.
[8]MOK T S,WU Y L,THONGPRASERT S,et al.Modern treatments in advanced non-small-cell lung cancer:temporal trends and effect on survival.A French PopulationBased Study[J].N Engl J Med,2015,361(10):947-957.
[9]KIM T J,LEE C T,JHEON S H,et al.Radiologic characteristics of surgically resected non-small cell lung cancer with ALK rearrangement or EGFR mutations[J].Ann Thorac Surg,2016,101(2):473-480.
[10]张绪超,陆舜,张力,等.中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)[J].中华病理学杂志,2013,42(6):402-406.
[11]CARPENTIER O,SELVAGGI L,JGU J,et al.Modern treatments in advanced Non-Small-Cell lung cancer:temporal trends and effect on survival.a French PopulationBased study[J].Clin Lung Cancer,2015,16(6):496-506.
[2]RAMALINGAM S S,OWONIKOKO T K,KHURI F R.Lung cancer:new biological insights and recent therapeutic advances[J].CA Cancer J Clin,2011,61(2):91-112.
[3]彭红,韩宝惠,李小青,等.1 279例肺癌患者临床特征及生存率分析[J].中国癌症杂志,2011,21(5):354-358.
[4]SACHER A G,DAHLBERG S E,HENG J,et al.Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer[J].JAMA Oncol,2016,2(3):313-320.
[5]WANG Y,CHEN J,DING W,et al.Clinical features and gene mutations of lung cancer patients 30years of age or younger[J].PLoS One,2015,10(9):e0136659.
[6]张仁锋,张岩,温丰标,等.6 058例肺癌患者病理类型和临床流行病学特征的分析[J].中国肺癌杂志,2016,19(3):129-135.
[7]AYYOUB M,MEMEO L,ALVAREZ-FERNNDEZ E,et al.Assessment of MAGE-A expression in resected nonsmall cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS[J].Cancer Immunol Res,2014,2(10):943-948.
[8]MOK T S,WU Y L,THONGPRASERT S,et al.Modern treatments in advanced non-small-cell lung cancer:temporal trends and effect on survival.A French PopulationBased Study[J].N Engl J Med,2015,361(10):947-957.
[9]KIM T J,LEE C T,JHEON S H,et al.Radiologic characteristics of surgically resected non-small cell lung cancer with ALK rearrangement or EGFR mutations[J].Ann Thorac Surg,2016,101(2):473-480.
[10]张绪超,陆舜,张力,等.中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)[J].中华病理学杂志,2013,42(6):402-406.
[11]CARPENTIER O,SELVAGGI L,JGU J,et al.Modern treatments in advanced Non-Small-Cell lung cancer:temporal trends and effect on survival.a French PopulationBased study[J].Clin Lung Cancer,2015,16(6):496-506.